Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07684456, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Patients who have received non-investigational anti-tumor therapies within 4 weeks prior to study drug administration.
Exclusion criterion 1
Patients who have received any major surgery(except for diagnostic procedures such as biopsy),or have sustained major trauma within 4 weeks to randomization;or is expected to undergo major surgery during the treatment.
Exclusion criterion 12
Patients who have received radiotherapy within 2 weeks to randomization.
Exclusion criterion 13
Male or female subjects with ECOG performance status scored 0-1.
Inclusion criterion 3
At least one measurable lesion present according to RECIST 1.1 criteria.
Inclusion criterion 8
Patients with other malignant tumor within 5 years to randomization excluding curatively treated cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cell carcinoma, and papillary thyroid carcinoma.
Exclusion criterion 15
Fertile males and females of childbearing potential must agree to use effective contraception (so do their partners, using hormonal or barrier contraception, or abstinence) during the study and within at least 6 months after the last dose. The blood or urine pregnancy test for female patients of childbearing potential prior to enrollment must be negative.
Inclusion criterion 12
Pregnant or lactating patients.
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07684456, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients who have fully understood the objectives, content, process of the study and possible adverse events, voluntarily serves as a subject and signs the informed consent form.
- Subjects aged ≥18 and ≤75.
- Male or female subjects with ECOG performance status scored 0-1.
- Patients who were diagnosed with HER-2 negative advanced breast cancer by histopathology.
- Patients with locally advanced,recurrent,or metastatic breast cancer.
- Patients who had received chemotherapy regimens, including at least one taxanes or anthracyclines.
- Patients with hormone receptor positive should have disease progression after endocrine therapy.
- At least one measurable lesion present according to RECIST 1.1 criteria.
- Expected survival time ≥ 12 weeks
- Baseline routine blood tests is normal.
- Liver and kidney function test results are normal.
- Fertile males and females of childbearing potential must agree to use effective contraception (so do their partners, using hormonal or barrier contraception, or abstinence) during the study and within at least 6 months after the last dose. The blood or urine pregnancy test for female patients of childbearing potential prior to enrollment must be negative.
Exclusion Criteria:
- Patients who have received non-investigational anti-tumor therapies within 4 weeks prior to study drug administration.
- Patients who have used Capecitabine or Utidelone within 6 months prior to randomization.
- Patients with breast cancer with CNS metastases leptomeningeal metastases.
- Patients with uncontrollable bone metastases,existing or recent risk of fracture, recent need for surgery or local radiotherapy, or other critical conditions.
- Patients with uncontrollable pleural effusion,pericardial effusion or ascites requiring repeated drainage(once a month or more)
- Patients with serious cardiovascular disease.
- Patients with mental illnesses which are hard to control, patients who lack legal capacity or have limited legal capacity.
- Patients with gastrointestinal disorders affecting oral administration.
- Patients with active infections and need systemic therapy currently.
- Patients with peripheral neuropathy grade≥2 during randomization.
- Patients with toxicity grade ≥2 which caused by prior anti-tumor therapy.(NCI-CTCAE 5.0,except for what is considered no safety risk such as alopecia by investigator.)
- Patients who have received any major surgery(except for diagnostic procedures such as biopsy),or have sustained major trauma within 4 weeks to randomization;or is expected to undergo major surgery during the treatment.
- Patients who have received radiotherapy within 2 weeks to randomization.
- Patients who have received interventional therapy in another clinical trail or have received other investigational treatments.
- Patients with other malignant tumor within 5 years to randomization excluding curatively treated cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cell carcinoma, and papillary thyroid carcinoma.
- Patients with allergy of caster oil:patients with previous fluorouracil medication history with severe allergy or known dihydropyrimidine dehydrogenase (DPD) deficiency;
- Pregnant or lactating patients.
- Patients who, in the opinion of the investigator, are not suitable to participate in this study.
Quoted from ClinicalTrials.gov, NCT07684456, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07684456, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.